These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38194770)

  • 1. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
    Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
    Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
    Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
    Epilepsia Open; 2024 Oct; 9(5):1643-1657. PubMed ID: 38962968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
    Frampton JE
    Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
    Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
    Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
    Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
    Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies.
    Gil-Nagel A; Cross JH; Devinsky O; Ceulemans B; Lagae L; Knupp K; Schoonjans AS; Ryvlin P; Thiele EA; Polega S; Lothe A; Nabbout R
    Epilepsia; 2024 Aug; 65(8):2186-2199. PubMed ID: 39030735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
    Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
    Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
    J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Wechsler RT; Burdette DE; Gidal BE; Hyslop A; McGoldrick PE; Thiele EA; Valeriano J
    Epilepsia Open; 2024 Oct; 9(5):1632-1642. PubMed ID: 39007525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review.
    Strzelczyk A; Becker H; Tako L; Hock S; Hattingen E; Rosenow F; Mann C
    Neurol Res Pract; 2024 Feb; 6(1):10. PubMed ID: 38383582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan JE; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Shore S; Agarwal A; Lock M; Farfel GM; Galer BS; Gammaitoni AR; Davis R; Gil-Nagel A
    JAMA Neurol; 2022 Jun; 79(6):554-564. PubMed ID: 35499850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.